Can-Fite BioPharma ($CANF) Stock Hub: FDA/EMA Phase III Status, Namodenoson and Piclidenoson

01Executive summary

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biotechnology company listed on NYSE American under $CANF. The company is built around a platform of orally administered small-molecule A3 adenosine receptor agonists, led by Namodenoson and Piclidenoson. The scientific story is broader than the market capitalization suggests: Namodenoson is being evaluated in advanced hepatocellular carcinoma, pancreatic cancer and MASH, while Piclidenoson is being developed in psoriasis and has a veterinary osteoarthritis angle through Vetbiolix.

The most recent official development is the August 12, 2026 Form 6-K. It reaffirms that Namodenoson holds FDA Fast Track and U.S. and European Orphan Drug designations for the HCC program and that the pivotal HCC trial was shaped with FDA and EMA input. It also reiterates Piclidenoson’s Phase III psoriasis path. This is useful regulatory confirmation, but not a new approval, designation, trial result or marketing submission. The July pancreatic milestones and ESMO acceptance remain relevant clinical-context catalysts.

At the same time, Piclidenoson moved into a more concrete pivotal setup. Can-Fite completed enrollment of the first 247 patients required for the pre-specified interim analysis of its randomized, double-blind, placebo-controlled Phase 3 psoriasis study. The company expects the interim efficacy and safety results in Q4 2026/Q1 2027.

That is a meaningful improvement in the story, but it does not erase the limitations. The Phase 2a study enrolled only 20 patients, was open-label, lacked a randomized comparator and included subgroup survival analysis. In biotech language, it is a signal, not proof. It supports further development, but it does not yet validate the drug as a commercial pancreatic cancer therapy.

The investment profile is therefore unusually binary and unusually fragile. The bull case rests on the possibility that a safe oral drug with multi-pathway biology can show enough disease control to attract partners or justify larger studies. The bear case rests on the fact that Can-Fite remains a nano-cap with limited cash, recurring operating losses, a long history of equity financing and multiple warrant structures that can cap upside or create selling pressure around rallies.

02Fast snapshot

03Company overview

Can-Fite BioPharma is an advanced clinical-stage biotechnology company developing small-molecule drugs for oncological, inflammatory and liver-related indications. The company’s platform is based on targeting the A3 adenosine receptor, or A3AR, a receptor that Can-Fite says is highly expressed in diseased cells and less expressed in normal cells. This biological selectivity is the foundation of the company’s repeated claim that its candidates have shown a favorable safety profile across a large clinical exposure base.

The story is not a single-product story. It has several branches: Namodenoson in hepatocellular carcinoma, pancreatic cancer and MASH; Piclidenoson in psoriasis and other inflammatory or rare disease areas; CF602 in erectile dysfunction; and a veterinary development path for Piclidenoson in canine osteoarthritis through Vetbiolix.

For equity investors, however, one asset currently dominates the narrative: Namodenoson. It is the asset with the strongest oncology relevance, the clearest regulatory designations, and the most important near-term catalyst path after the July 2026 pancreatic cancer update.

04Why $CANF matters now

The July 1, 2026 update changed the short-term focus of the stock. Before that release, Can-Fite had already reported favorable safety and preliminary disease stabilization observations in pancreatic cancer. The latest filing sharpened the story by stating that the Phase 2a pancreatic cancer study achieved its primary safety endpoint and showed durable survival outcomes in advanced disease.

The details matter. The trial enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed after standard therapies. Fourteen received Namodenoson as third-line treatment, five as second-line treatment and one as fourth-line treatment. The drug was described as well tolerated, with a safety profile consistent with prior clinical trials.

The survival analysis focused on eight third-line patients who survived at least two months after treatment initiation, excluding patients with rapidly progressive disease considered unlikely to derive benefit from systemic therapy. Among those eight evaluable third-line patients, the company reported median overall survival exceeding five months, 62.5% survival at five months or longer, 37.5% survival at seven months or longer, two patients alive at data cutoff, and durable disease control including progression-free survival beyond seven months.

The strongest individual observation came from the second-line setting, where one patient remained alive more than 18 months after starting Namodenoson. That is not enough to prove efficacy, but it is enough to explain why the company now wants to test the drug in a larger Phase 2b combination setting.

05Pipeline map

06Namodenoson: the core asset

Namodenoson is a small orally bioavailable drug that binds selectively to the A3 adenosine receptor. Can-Fite’s core argument is that A3AR is highly expressed in diseased cells while showing low expression in normal cells, potentially helping explain the favorable safety profile observed across development programs.

In oncology, Namodenoson is being positioned as a multi-pathway drug rather than a single mutation-targeted therapy. Can-Fite has highlighted preclinical evidence involving RAS, Wnt/β-catenin, NF-κB, Hedgehog signaling and multidrug-resistance pathways in pancreatic cancer models. This gives the company a biological rationale for combination therapy, especially in pancreatic cancer where resistance and pathway redundancy are major clinical problems.

The scientific idea is interesting because pancreatic ductal adenocarcinoma is one of the hardest oncology settings. Many treatments fail because monotherapy activity is weak, tumor biology is aggressive, and patients frequently arrive in later lines with poor performance status. A drug that is safe enough to combine with gemcitabine-based chemotherapy could have more practical value than a drug that shows marginal monotherapy activity but cannot be layered into standard regimens.

That is the logic behind the Phase 2b transition. Can-Fite is not trying to prove that the Phase 2a alone is registration-quality. It is trying to use the Phase 2a as a bridge toward a better-designed combination study.

07Pancreatic cancer: the fresh catalyst

Pancreatic cancer is now the most visible near-term story for $CANF. The Phase 2a study evaluated oral Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease had progressed after at least first-line therapy or who refused standard treatment. Patients received Namodenoson 25 mg twice daily in consecutive 28-day cycles.

The March and April 2026 updates established the first layer of the story: safety, disease stabilization in more than 30% of evaluable patients, prolonged treatment duration including one patient beyond 16 months, and 35% of patients remaining on therapy and follow-up at the time of the April update. The July 1 filing then added the more mature survival-oriented language and confirmed that the safety endpoint had been achieved.

What still needs proof

The Phase 2a still cannot answer the most important questions. It cannot prove whether Namodenoson improves survival versus standard care. It cannot show whether the signal is durable across a larger population. It cannot determine whether the drug adds meaningful benefit when combined with chemotherapy. It cannot yet define a commercial path.

Those questions move to Phase 2b. The structure of the next study will matter enormously: final treatment backbone, comparator, line of treatment, patient selection, endpoints, statistical assumptions, geography, enrollment speed and funding. The market will likely punish vague design language and reward a clear protocol with credible endpoints.

08Hepatocellular carcinoma: the late-stage anchor

The HCC program remains the most advanced Namodenoson program. The pivotal Phase 3 trial is focused on advanced hepatocellular carcinoma in patients with Child-Pugh B7 cirrhosis whose disease has progressed on at least one prior line of therapy. The study is designed as a randomized, double-blind, placebo-controlled trial, with patients assigned in a 2:1 ratio to Namodenoson or placebo.

This matters because HCC patients with impaired liver function are difficult to treat. Many systemic therapies are developed in patients with better liver reserve, leaving a clinically important gap for those with more fragile liver function. Can-Fite’s prior HCC work has repeatedly pointed to a possible signal in Child-Pugh B7 patients, which is why the Phase 3 program is important.

The August 12 Form 6-K reiterates that the pivotal study is being conducted under FDA and EMA guidance and is intended to support possible U.S. and European submissions if its endpoints are met. It also reiterates FDA Fast Track status and U.S. and European Orphan Drug designations for the HCC program. These designations can clarify or facilitate the regulatory path, but they do not establish efficacy, guarantee approval or replace a successful Phase III outcome. The filing does not announce a new designation or a submitted marketing application.

For $CANF, the HCC program is both opportunity and burden. It is opportunity because a positive Phase 3 survival result would transform the company. It is burden because Phase 3 oncology trials are expensive, slow and unforgiving. In a company with Can-Fite’s current market cap and financing history, investors cannot separate the science from the capital requirement.

09MASH: large market, different risk

Namodenoson is also being evaluated in MASH, formerly known as NASH. This is a very large potential market, but it is also one of the most competitive and clinically demanding areas in liver drug development. The Phase 2b program gives Can-Fite exposure to metabolic liver disease, but the bar for meaningful differentiation is high.

The MASH thesis is different from the oncology thesis. In cancer, investors usually focus on survival, response, disease control and treatment line. In MASH, the questions are histology, fibrosis, inflammation, durability, safety, tolerability and positioning versus larger players. A small company can create value with strong Phase 2b data, but the market will not give full credit without clarity on endpoints and partnership potential.

MASH should therefore be viewed as a real pipeline component, but not the immediate driver of the July 2026 $CANF setup. The near-term market story is still pancreatic cancer and the transition toward a Phase 2b combination trial.

10Piclidenoson: psoriasis and veterinary optionality

Piclidenoson is Can-Fite’s inflammatory disease asset and now carries one of the company’s clearest dated catalysts. On July 6, 2026, Can-Fite announced completion of enrollment of the first 247 patients required for the pre-specified interim analysis in its pivotal randomized, double-blind, placebo-controlled Phase 3 psoriasis study. The interim analysis will assess efficacy and safety, with results expected in Q4 2026/Q1 2027.

The psoriasis study uses oral Piclidenoson 3 mg twice daily versus placebo, with co-primary efficacy objectives based on PASI 75 and an sPGA score of 0 or 1 at Week 16. The August 12 filing reiterates that this Phase III program operates under an FDA/EMA-established regulatory framework; it does not report a new regulatory milestone or new efficacy data. The oral profile is strategically interesting, but the trial still must show competitive efficacy in a crowded market.

The veterinary branch is unusual for a human biotech stock, but it should not be ignored. In March 2026, Can-Fite announced that Vetbiolix had completed enrollment in a Phase 2 canine osteoarthritis study of Piclidenoson, with data expected in Q3 2026. The company has described the Vetbiolix agreement as worth up to $325 million over the next decade, subject to successful development and commercialization.

This creates an additional 2026 watch item, but it should be weighed carefully. Projected deal value is not the same as guaranteed cash. Milestones and royalties depend on clinical success, regulatory progress, commercialization and partner execution.

11Financial position and runway

As of December 31, 2025, Can-Fite reported $5.5 million in cash and cash equivalents and $3.0 million in short-term deposits, for a combined liquidity base of approximately $8.5 million. The company reported 2025 revenue of $0.405 million, research and development expenses of $6.693 million, general and administrative expenses of $3.662 million and a net loss of $9.828 million.

The 20-F states that, based on current projections and plans, existing financial resources were expected to be sufficient to meet requirements for the next twelve months from the issuance date of the annual report. That is helpful, but it does not remove future financing risk. The same filing also states that the company will need to raise additional capital in the future and that capital raising may dilute existing shareholders.

The burn profile is not extreme by large biotech standards, but it is large relative to Can-Fite’s market value. This is the key problem. A company with several clinical programs, multiple Phase 2/3 paths and a nano-cap valuation cannot fund itself comfortably without recurring access to capital markets, partners or milestone payments.

12Capital structure and dilution risk

The dilution issue is central to $CANF. The company has repeatedly used equity financing, warrants, ATM issuance and warrant inducement transactions. In March 2026, Can-Fite announced warrant exercises generating approximately $4.3 million in gross proceeds, and in exchange issued new warrants to purchase up to 1,591,738 ADSs with an exercise price of $5.00 per ADS.

That kind of financing is not unusual for micro-cap biotech. It is also not harmless. Warrants can create future dilution, and resale registration statements can create selling overhang. When a stock rallies on clinical news, traders often immediately look at warrant strikes, shelf capacity, ATM activity and recent placement-agent history.

The 20-F shows the scale of dilution over time. Ordinary shares outstanding increased from 994,394 at December 31, 2024 to 2,618,425 at December 31, 2025, and the beneficial ownership table used 4,285,093 ordinary shares outstanding as of March 25, 2026. Since each ADS represents two ordinary shares, the effective ADS-equivalent count is much smaller than the ordinary share count, but the direction is clear: the share base has expanded materially.

13Analyst coverage and market expectations

Sell-side coverage appears limited. This update does not rely on third-party target aggregators because the underlying analyst notes were not available as primary documents for direct verification. In a stock with a very small market capitalization and repeated split-adjusted share-count changes, headline targets can become stale quickly.

The practical market point is more useful than any isolated target: $CANF is likely to trade primarily on clinical data, trial-design clarity, financing terms, warrant supply and partnership language. Those variables can move the equity value far more than conventional earnings-based valuation.

14Institutional, insider and retail sentiment

$CANF is too small and too catalyst-driven to behave like an institutionally anchored biotech. The shareholder base is more likely to be influenced by event-driven traders, warrant holders, specialist biotech investors and retail momentum flows than by long-only fundamental institutions. That makes the stock highly sensitive to headlines.

Insider ownership and institutional presence should be reviewed directly through SEC filings before any trade decision, because tiny changes in beneficial ownership can look large in percentage terms when the denominator is small. The main durable observation is that the company’s capitalization profile gives public-market financing participants significant influence over the trading setup.

Retail sentiment around names like $CANF usually improves quickly after cancer data headlines and fades just as quickly when the market refocuses on cash, warrants or the lack of randomized proof. For this reason, sentiment should be treated as a volatility input rather than an investment foundation. These observations reflect the behavior of non-professional traders, not institutional analyst views.

15Bull case

The bull case starts with the idea that Namodenoson’s safety profile is clinically useful. In late-line pancreatic cancer, a drug that can be administered orally and tolerated in fragile patients may have value if it shows even modest additive benefit in combination therapy. The July 2026 survival observations do not prove this, but they support further testing.

The second bull argument is that Can-Fite has a broader platform than its market cap implies. HCC Phase 3, MASH Phase 2b, pancreatic Phase 2b planning, psoriasis Phase 3 and veterinary osteoarthritis create several possible inflection points. A partnership or licensing deal could matter disproportionately because the enterprise value is so small.

The third bull argument is technical and structural. Nano-cap biotech stocks can rerate violently when a low valuation collides with credible clinical news. If the market begins to believe that the PDAC data are more than noise, the stock could attract speculative biotech flow.

16Bear case

The bear case is straightforward. The pancreatic cancer dataset is small, uncontrolled and exploratory. In oncology, especially in pancreatic cancer, many early signals fail once tested in larger randomized studies. Survival subgroup analyses can be encouraging but are not definitive.

The second bear argument is financial. Can-Fite’s cash base is modest, its operating losses are recurring and the company’s development agenda is broad. Without a major partnership or non-dilutive capital source, additional equity financing remains a realistic expectation.

The third bear argument is market structure. Nano-cap biotech stocks with repeated financing history often struggle to hold gains. Even when a clinical headline is good, traders may quickly ask whether the move will be used to raise capital.

17Red flags to monitor

18Catalyst timeline

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

19Bottom line

$CANF is a real clinical-stage biotech story wrapped inside a fragile nano-cap capital structure. The August 12 filing improves regulatory-path visibility by reaffirming FDA/EMA status for the Namodenoson HCC and Piclidenoson psoriasis Phase III programs. It does not, by itself, improve the clinical probability of success: there is no new approval, agency designation, efficacy dataset or marketing submission. The July pancreatic sequence, ESMO visibility and the psoriasis interim analysis remain the more consequential clinical catalysts.

But the stock is not de-risked. The PDAC dataset is small and open-label, the psoriasis interim analysis remains binary, the HCC Phase 3 path remains long, MASH is competitive, and the company’s financing history is a major part of the investment risk. The cleanest editorial conclusion is that Can-Fite deserves a place on the biotech catalyst radar, but only with a full understanding of dilution, trial design and execution risk.